Last reviewed · How we verify
rFVIII (BAY81-8973) on demand
rFVIII (BAY81-8973) is a recombinant factor VIII replacement therapy that mimics the natural protein to treat bleeding episodes in patients with hemophilia A.
rFVIII (BAY81-8973) is a recombinant factor VIII replacement therapy that mimics the natural protein to treat bleeding episodes in patients with hemophilia A. Used for On-demand treatment of bleeding episodes in patients with hemophilia A.
At a glance
| Generic name | rFVIII (BAY81-8973) on demand |
|---|---|
| Sponsor | Bayer |
| Drug class | recombinant factor VIII replacement therapy |
| Target | Factor VIII |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
rFVIII (BAY81-8973) works by replacing the deficient or defective factor VIII protein in patients with hemophilia A, allowing for proper blood clotting and preventing excessive bleeding. This recombinant protein is designed to have a similar structure and function to the natural factor VIII protein, making it an effective treatment option for patients with this condition.
Approved indications
- On-demand treatment of bleeding episodes in patients with hemophilia A
Common side effects
- Inj site reaction
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rFVIII (BAY81-8973) on demand CI brief — competitive landscape report
- rFVIII (BAY81-8973) on demand updates RSS · CI watch RSS
- Bayer portfolio CI